Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28290789 | 0.84 | ALDH1A1 (0.57) | ALDH1A1PKMKMT2ASOS1POLB | |
| SCHEMBL28290761 | 0.83 | MITF (0.62) | ALDH1A1PKMKMT2ASOS1POLB | |
| SCHEMBL3504600 | 0.83 | ALDH1A1 (0.68) | ALDH1A1PKMKMT2ASOS1POLB | |
| SCHEMBL28334488 | 0.83 | ALDH1A1 (0.68) | ALDH1A1PKMKMT2ASOS1POLB | |
| SCHEMBL29170726 | 0.81 | ALDH1A1 (0.66) | ALDH1A1PKMKMT2ASOS1POLB | |
| SCHEMBL28290787 | 0.81 | ALDH1A1 (0.54) | ALDH1A1PKMKMT2ASOS1POLB | |
| SCHEMBL13431485 | 0.81 | ALDH1A1 (0.75) | ALDH1A1PKMKMT2ASOS1POLB | |
| SCHEMBL10825501 | 0.80 | ALDH1A1 (0.68) | ALDH1A1PKMKMT2ASOS1POLB | |
| SCHEMBL14181603 | 0.80 | ALDH1A1 (0.73) | ALDH1A1PKMKMT2ASOS1POLB | |
| SCHEMBL28290784 | 0.78 | ALDH1A1 (0.53) | ALDH1A1PKMKMT2ASOS1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1310510-B1 | Topologically segregated, encoded solid phase libraries | AVENTIS PHARMA INC (US) | 2007-07-11 | — | — | EP | claimed |
| EP-0705279-B1 | TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES | SELECTIDE CORP (US) | 2003-02-19 | — | — | EP | claimed |
| US-5939568-A | Accelerated catalysis of olefinic epoxidations | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-08-17 | — | — | US | claimed |
| CN-109706198-A | A kind of method that online enzyme process closes nitro imidazole derivatives | 浙江工业大学 | 2019-05-03 | — | — | CN | disclosed |
| EP-1727540-A4 | MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AND METHODS OF USE | UNIV CALIFORNIA (US) | 2009-07-22 | — | — | EP | disclosed |
| EP-1310510-B1 | Topologically segregated, encoded solid phase libraries | AVENTIS PHARMA INC (US) | 2007-07-11 | — | — | EP | disclosed |
| EP-1727540-A1 | MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AND METHODS OF USE | The Regents Of the University of California (US) | 2006-12-06 | — | — | EP | disclosed |
| US-7141561-B2 | Substituted diaryl heterocycles, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-11-28 | — | — | US | disclosed |
| WO-2005094817-A1 | MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-10-13 | — | — | WO | disclosed |
| US-6828427-B1 | Oligomeric aminodiol-containing compounds, libraries thereof, and process of preparing the same | ISIS PHARMACEUTICALS, INC. | 2004-12-07 | — | — | US | disclosed |
| US-20040132752-A1 | Substituted diaryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-08 | — | — | US | disclosed |
| EP-0705279-B1 | TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES | SELECTIDE CORP (US) | 2003-02-19 | — | — | EP | disclosed |
| US-6372883-B1 | FOR THERAPY AND PROPHYLAXIS OF INFECTIONS CAUSED BY HEPATITIS C, HEPATITIS G AND HUMAN GB VIRUSES | HOFFMANN-LA ROCHE INC. | 2002-04-16 | — | — | US | disclosed |
| US-6359144-B1 | BIOSYNTHESIS; SCREENING | LION BIOSCIENCE AG (DE) | 2002-03-19 | — | — | US | disclosed |
| US-6316626-B1 | Amine compounds and combinatorial libraries comprising same | ISIS PHARMACEUTICALS, INC. | 2001-11-13 | — | — | US | disclosed |
| US-6251854-B1 | COMPRISING AN OLIGOPETIDE INCLUDING A GUANIDINIUM-CONTAINING AMINO ACID SUCH AS ARGININE, AND A COMPOUND SUCH AS 2H-3-(4-FLUOROBENZYL)-7-(BUT-2-YL)-8-(3-METHYLBUTYL)-DIAZOLIDINE(1,2 -B)DIHYDROIMIDAZOLE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-06-26 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-5939568-A | Accelerated catalysis of olefinic epoxidations | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-08-17 | — | — | US | disclosed |
| US-5780653-A | Nitrophenyl, 10-deacetylated substituted taxol derivatives as dual functional cytotoxic/radiosensitizers | VIVORX PHARMACEUTICALS, INC. (US) | 1998-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132752-A1 | Substituted diaryl heterocycles, process for their preparation and their use as medicaments | GPR119, GLP1R, SLC5A2 | ALDH1A1 1096/4885PKM 1528/4885KMT2A 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.